There are risks with subcutaneous immunotherapy injections, and I want to be transparent and precise about what they are, how common they are, and how they are managed at Vatsalya Hospital, Varanasi, because this transparency is what allows families to make an informed decision about treatment. The risks divide into local reactions and systemic reactions. Local reactions at the injection site are the most common: a wheal, redness, and itching at the injection site that typically develops within twenty minutes and resolves within a few hours. These reactions are uncomfortable and indicate that the dose is approaching the upper range the child's immune system is ready for at that stage, but they are not dangerous. Their occurrence is a signal to the treating clinician to hold the dose rather than increasing it at the next visit until the reaction pattern settles. Systemic reactions, in which the immune response extends beyond the injection site, are less common but are the primary safety concern with SCIT. A mild systemic reaction might involve sneezing, rhinorrhea, urticaria (hives), or a mild sensation of warmth or itching distant from the injection site. A more significant systemic reaction can involve bronchospasm (tightening of the airways producing wheeze and breathlessness) or, rarely, anaphylaxis, a severe and potentially life-threatening systemic allergic response. The incidence of severe systemic reactions with SCIT in appropriately selected and managed patients is low, but it is not zero, which is why every SCIT injection is given in the clinic and not at home, and why every child remains under observation for thirty minutes after each injection, since the vast majority of systemic reactions occur within this window. At Vatsalya Hospital, the clinic is equipped to recognise and manage systemic reactions immediately: adrenaline (epinephrine), antihistamines, bronchodilators, and resuscitation equipment are immediately available, and I or a trained clinician is present throughout the observation period. The risk of systemic reaction is highest during the build-up phase when the dose is being escalated, and it is one of the reasons that poorly controlled asthma is a contraindication to SCIT injection on that visit: the airways are already in an inflamed, reactive state, and introducing an allergen dose in this context increases the systemic reaction risk substantially. The risk management framework for SCIT is well established, the safety record in appropriately managed patients is good, and the three-decade evidence base for SCIT reflects millions of doses administered safely worldwide. The commitment to thirty minutes of post-injection observation at Vatsalya Hospital is not optional: it is the safety net that makes SCIT a manageable risk rather than an unacceptable one.
Written by Dr. Divyank Pathak, MBBS, MD (Paediatrics), IFPCCM, DPAA, FNPP, DPSM, FAAP, Director and Senior Consultant Paediatrician, Pediatric Critical Care and Allergy and Asthma Specialist, Vatsalya Superspeciality Children Hospital, Varanasi 221002. Phone: +91 9838713111.
